Overview and Scope
Insomnia is a sleep disorder in which the patient has trouble falling or staying asleep. Depending on the duration, the condition is either short-term (acute) or long-term (chronic). Drugs, digital therapeutics, and devices are used to treat insomnia conditions.
Sizing and Forecast
The insomnia market size has grown strongly in recent years. It will grow from $4.72 billion in 2023 to $4.97 billion in 2024 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to increased stress levels, prevalence of mental health conditions, shift work and irregular work hours, increased awareness and diagnosis, high consumption of stimulants.
The insomnia market size is expected to see strong growth in the next few years. It will grow to $6.09 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to global health crisis impact, increasing awareness of sleep hygiene, emphasis on mental health and wellness, government initiatives for sleep health, influence of social determinants. Major trends in the forecast period include digital health solutions for sleep monitoring, cognitive behavioral therapy for insomnia , telehealth for sleep consultations, integration of sleep health into primary care, research on novel therapeutic targets.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/insomnia-global-market-report
Segmentation & Regional Insights
The insomnia market covered in this report is segmented –
1) By Therapy Type: Non-Pharmacological Therapy, Pharmacological Therapy
2) By Drug Class: Anti-Depressants, Melatonin Antagonist, Benzodiazepines, Nonbenzodiazepines, Orexin Antagonist, Other Drug Classes
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
North America was the largest region in the insomnia market in 2023. The regions covered in the insomnia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=12120&type=smp
Major Driver Impacting Market Growth
The surge in work-related Stress is expected to propel the growth of the insomnia market going forward. Work-related Stress refers to harmful emotional and physical responses that occur when the work demands, and pressures do not match the worker’s resources, capabilities, or knowledge. Job stress can lead to poor health, including insomnia. Depending on the severity of insomnia, the patients are treated with drug or cognitive-behavioral therapies, among others. Thus, the surge in work-related Stress is boosting sales in the insomnia market. For instance, in October 2021, according to a survey of 1,500 US employees conducted by the American Psychology Association, a US-based professional organization of psychologists, approximately 59% of the respondents were experiencing work-related stress in 2021. Furthermore, in November 2022, according to the US Bureau of Labor Statistics, a US-based principal fact-finding agency of the US government, the total rate of injuries increased in 2021 to 2.3 cases per 100 full-time equivalent workers, up from 2.2 cases in 2020. Real-reported injuries in 2021 increased by 6.3% (2.2 million cases) compared to 2020 (2.1 million cases). Therefore, the surge in work-related Stress is driving the growth of the insomnia market.
Key Industry Players
Major companies operating in the insomnia market report are Pfizer Inc., Merck & Co Inc., Sanofi S.A., GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Koninklijke Philips N.V., Viatris Inc., Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Eisai Co.Ltd., UCLA Health Insomnia Clinic, Jazz Pharmaceuticals PLC, Aurobindo Pharma Limited, Purdue Pharma LP, Cipla Inc., Dr. Reddy’s Laboratories Ltd., Zydus Lifesciences Limited, Lupin Limited, Mallinckrodt Pharmaceuticals Plc., Fisher & Paykel Healthcare Corporation Limited, ResMed Inc., Sunovion Pharmaceuticals Inc., Casper Sleep Inc., Biocodex Inc., Vanda Pharmaceuticals Inc., Pernix Therapeutics Holdings Inc., SleepScore Labs, Alpha-Stim, Neurim Pharmaceuticals Ltd., NightWare Inc.
The insomnia market report table of contents includes:
1. Executive Summary
2. Insomnia Market Characteristics
3. Insomnia Market Trends And Strategies
4. Insomnia Market – Macro Economic Scenario
5. Global Insomnia Market Size and Growth
.
.
.
31. Insomnia Market Other Major And Innovative Companies
32. Global Insomnia Market Competitive Benchmarking
33. Global Insomnia Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Insomnia Market
35. Insomnia Market Future Outlook and Potential Analysis
36.Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
